QIAGEN today announced plans to combine its three Maryland sites into two campuses and invest an additional $10 million to accommodate expected future growth. The company will close its current site at Gaithersburg, Maryland and move the Gaithersburg activities to nearby Germantown, Maryland, by early 2015.
February U.S. manufacturing technology orders totaled $354.40 million according to AMT - The...
Vetter, a contract development and manufacturing organization (CDMO), has introduced two...
PuraMed BioScience announced today that the company is moving forward with the development of...
DBV Technologies announced today a research collaboration agreement with the French National Genotyping Center (CNG) at the French Alternative energies and atomic energy commission.
Integrated Project Services, Inc. (IPS) announced the expansion of operations with the opening of a new IPS location in Irvine, California.
Thanks to a high level of access to healthcare insurance and reimbursement, coupled with increasing demand for healthcare services from an expanding elderly population, the South Korean pharmaceutical market is expected to climb in value from $19.3 billion in 2013 to $24.3 billion by 2020.
Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing targeted payload immunotherapeutics for the treatment of advanced cancers, announced that it started a collaboration with IsoTherapeutics Group of Houston, TX to complete studies required for introduction of a new manufacturing process for Actimab-A.
Halozyme Therapeutics has announced that as a result of a recommendation received yesterday from an independent Data Monitoring Committee (DMC), it is temporarily halting patient enrollment and dosing of PEGPH20 in an ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer.
Matcon Group Limited announced today the relocation of its USA Operation from Sewell, New Jersey to Elmhurst, Illinois. The Elmhurst facility is home to The Fitzpatrick Company. Both Matcon and Fitzpatrick are companies within the IDEX Material Processing Technologies (MPT) Platform; the combined location will form an IDEX MPT Center of Excellence.
The current buzz-term “Big Data” may be slightly misleading in the strictest sense. The concept is nothing new. Most manufacturers are quite accustomed to having “big,” some might say huge, amounts of data flowing throughout their organizations, but have historically lacked the context that gives that data actionable meaning—giving birth to the oft used phrase, “data rich, but information poor.”
UPM, a division of Gregory Pharmaceutical Holdings, Inc., has reached an agreement with Amerigen Pharmaceuticals, Inc. to commercially manufacture two ANDA products for a 10 year supply term.
Evotec AG has announced a research collaboration and licensing deal with Debiopharm Group Lausanne, Switzerland. The objective of this collaboration is to identify and develop novel compounds having the potential to treat multiple forms of solid tumors and leukemias with defined genetic alterations.
EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, today announced they have signed a research agreement with Pfizer Inc. and the Broad Institute in Cambridge, Massachusetts, U.S. The collaboration is focused on the genomic profiling of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) patients.
Evotec AG today announced that it has entered into a research alliance with Panion Ltd, a subsidiary of Convergence Pharmaceuticals Holdings Ltd. Convergence is a UK company focused on the development of novel, high value analgesics to treat chronic pain.
Vetter has announced significant progress in its solution for state-of-the-art product packaging, designed to support the prevention of product counterfeiting. This innovative development is in response to expanded requirements by official regulatory agencies that require manufacturers to have clear identification of drugs on packaging.
Information about the health of a control system, the I/O systems, field devices and final control elements can be critical for plant operation and uptime. Timely diagnostic information can mean the difference between a quick repair and hours or days of unplanned downtime.
Approximately 25% of drugs in development worldwide are classified as highly potent, with this percentage expected to grow over the coming years. While such highly potent compounds can have significant benefits in the treatment of certain medical conditions, they present substantial challenges to the pharmaceutical industry.
Carolina Medical Products, Inc. has officially changed its name to CMP Pharma. This new name more appropriately reflects the nature of its current business as a specialty pharmaceutical company focused on niche products that address critical patient needs.
Under terms of the agreement, Corning Life Sciences and ATCC will co-develop new applications for existing ATCC and Corning cell biology products; provide researchers with increased access to knowledgeable field scientists and information; and participate in joint marketing initiatives.
No two packaging projects are alike and in order to make it all work and to keep everything on track and everyone happy you need to have a flexible, responsive and quality-driven organizations. Reed-Lane has deftly combined these qualities along with recent investments to create a truly flexible contract packaging operation.
Baxter International has announced plans to create two separate, independent global healthcare companies -- one focused on developing and marketing innovative biopharmaceuticals and the other on life-saving medical products.
BioClinica, Inc., a today announced that it recently penned $30 million in multi-year contract renewals with two major pharmaceutical companies.
Agenus Inc. announced that GlaxoSmithKline’s MAGRIT i study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3 ii cancer immunotherapeutic trial in non-small cell lung cancer patients, which contains Agenus’QS-21 Stimulon ® adjuvant, did not meet its first or second co-primary endpoint.
Itonis, Inc. is pleased to announce that Charles Hensley, PhD., the inventor of the Zicam® cold remedy, and his team have completed their evaluation of the manufactured samples of Emesyl, the company's over-the-counter homeopathic product for nausea relief.
According to the report, Global Antibody Drug Conjugate Market Outlook 2018, backed by improved understanding and better technology, the ADC market is anticipated to reach US$ 3.45 Billion by 2018.
Five Prime Therapeutics and Bristol-Myers Squibb have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies directed toward targets identified in two undisclosed immune checkpoint pathways using Five Prime's proprietary target discovery platform.
How important are intuitive, durable and clean controls for equipment used in your business? As a practical matter, controls that require operators to actually touch them, wearing gloves or not, can never be really clean, however many protocols or chemicals are employed.
- Page 1